ArticleFrontiers in immunology2022

Vaccine-based clinical protection against SARS-CoV-2 infection and the humoral immune response: A 1-year follow-up study of patients with multiple sclerosis receiving ocrelizumab.

Saskia Räuber et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.